This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $361, marking a +1.97% move from the previous day.
SmileDirectClub (SDC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
SmileDirectClub (SDC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AmerisourceBergen (ABC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 6.38% and 4.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
McKesson (MCK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $359.24, marking a -1.11% move from the previous day.
Conmed (CNMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 10% and 10.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.
DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
What's in Store for West Pharmaceutical (WST) in Q1 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $359.27, marking a +1.05% move from the previous day.
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
McKesson (MCK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $362, moving -0.64% from the previous trading session.
Intuitive Surgical (ISRG) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
McKesson (MCK) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $362.99, moving -0.21% from the previous trading session.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $354.48 in the latest trading session, marking a +1.45% move from the prior day.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.